A Phase II Pilot Study of Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Carboplatin; Docetaxel; Estramustine
- Indications Prostate cancer
- Focus Therapeutic Use
- 22 May 2014 Biomarkers information updated
- 23 Jun 2009 Additional lead trial centres and investigators identified as reported by ClinicalTrials.gov.
- 31 May 2007 Status changed from recruiting to completed.